Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Invested Capital (2016 - 2025)

Historic Invested Capital for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $89.2 million.

  • Akebia Therapeutics' Invested Capital rose 84070.72% to $89.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.2 million, marking a year-over-year increase of 84070.72%. This contributed to the annual value of -$10.5 million for FY2024, which is 35596.49% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Invested Capital is $89.2 million, which was up 84070.72% from $76.3 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Invested Capital high stood at $213.9 million for Q1 2021, and its period low was -$1.5 billion during Q3 2022.
  • Over the past 5 years, Akebia Therapeutics' median Invested Capital value was $71.1 million (recorded in 2025), while the average stood at -$12.8 million.
  • In the last 5 years, Akebia Therapeutics' Invested Capital crashed by 118276.19% in 2022 and then skyrocketed by 236248.7% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Invested Capital (Quarter) stood at $171.6 million in 2021, then crashed by 58.43% to $71.3 million in 2022, then tumbled by 94.25% to $4.1 million in 2023, then plummeted by 355.96% to -$10.5 million in 2024, then soared by 950.49% to $89.2 million in 2025.
  • Its last three reported values are $89.2 million in Q3 2025, $76.3 million for Q2 2025, and $71.1 million during Q1 2025.